SLC5A2 and chronic kidney disease: This exploratory study aimed to evaluate the effectiveness of finerenone in patients with nondiabetic CKD who had previously been treated with standard therapeutic regimens, including renin–angiotensin–aldosterone system (RAAS) inhibitors and sodium–glucose co-transporter 2 (SGLT2) inhibitors, for managing albuminuria and estimated glomerular filtration rate (eGFR).